Can I get it?
Yes, if a doctor decides it is right for you. Finasteride is authorised in the EU and can be prescribed after a medical review.
An EU-licensed doctor reviews your case and, if eligible, issues an electronic prescription valid in any pharmacy in Spain. Consultation €15/month, refunded if the doctor decides it is not safe to prescribe.

Full refund if a review is not approved · Medication, if prescribed, is dispensed and paid for separately at a pharmacy.
IN PLAIN TERMS
Finasteride is a daily 1 mg tablet, and it is one of the few hair-loss medicines that is formally authorised for this purpose in EU countries. It works by lowering DHT, a hormone made from testosterone that gradually shrinks hair follicles in male pattern hair loss. It is authorised for men only, and it is not for women. The most talked-about side effects are sexual ones, such as lower sex drive or difficulty getting an erection; in the trials these affected about 4 men in 100 in the first year compared with about 2 in 100 taking a dummy tablet, and European regulators also require a warning about mood changes, including depression and suicidal thoughts.
Finasteride has been authorised for use in the EU since 1 February 1999, so a licensed doctor can prescribe it when it is clinically appropriate for you.
Yes, if a doctor decides it is right for you. Finasteride is authorised in the EU and can be prescribed after a medical review.
Our doctors review every Hair growth option and recommend what fits your history and goals.
See all Hair growth optionsEvery trial behind Finasteride is listed below with how many people took part and whether the results are peer-reviewed or a company announcement.
Jump to the studiesLocal consultation facts
Yes. People in Valencia, Spain, can request an online doctor consultation about Finasteride with Hi-Doctor. A licensed EU doctor reviews the case and issues a prescription only when clinically appropriate. If approved, the electronic prescription arrives as a QR code that can be dispensed directly in Spain.
Availability
Finasteride is available to residents of Spain through the online consultation. A prescription follows only if the doctor approves it.
How the EU prescription works where you are: In Spain, an approved prescription arrives electronically with a QR code for direct dispensing.
VERIFIED EVIDENCE
WHAT IT IS
It blocks the enzyme that turns testosterone into DHT, the hormone that shrinks hair follicles in male pattern hair loss, so less DHT reaches the scalp.
DEVELOPMENT STAGE
Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.
| TRIAL / NCT | POPULATION | PARTICIPANTS | STATUS | READOUT / COMPLETION |
|---|---|---|---|---|
| Finasteride Male Pattern Hair Loss Study Group (two 1-year randomised placebo-controlled trials plus a blinded second-year extension) | Men aged 18-41 with vertex androgenetic alopecia | 1,553 | Read out | 1998-10-01 |
Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.
| DOSE OR GROUP | MEAN WEIGHT CHANGE | WEEKS |
|---|---|---|
| 1 mg daily | +107 hairs vs placebo, counted in a 1-inch (5.1 cm2) circle of balding vertex scalp (baseline 876 hairs) | 52 |
| 1 mg daily | +138 hairs vs placebo, counted in a 1-inch (5.1 cm2) circle of balding vertex scalp | 104 |
The trials enrolled only men aged 18-41 with vertex-pattern loss, did not establish an effect on bitemporal recession or late-stage hair loss, and the EU product information states that continued use is needed to keep the benefit.
Last reviewed 2026-07-27
NAMED SAFETY SIGNALS
In the phase III trials, drug-related sexual adverse reactions were reported in 3.8% of men on finasteride 1 mg vs 2.1% on placebo during the first 12 months, falling to 0.6% over the following four years. About 1% of men in each group stopped treatment for this reason in the first 12 months (EU SmPC, section 4.8).
Classified as uncommon (1 in 1,000 to 1 in 100) in the EU SmPC. Reported in 1.8% of men on finasteride 1 mg vs 1.3% on placebo.
Classified as uncommon (1 in 1,000 to 1 in 100) in the EU SmPC. Reported in 1.3% of men on finasteride 1 mg vs 0.7% on placebo.
Classified as uncommon in the EU SmPC. Decreased ejaculate volume reported in 0.8% of men on finasteride 1 mg vs 0.4% on placebo.
Persistence of decreased libido, erectile dysfunction and ejaculation disorders after finasteride is stopped has been reported in post-marketing use. Frequency is not known because these are spontaneous reports.
Depression is listed as uncommon; anxiety and suicidal ideation are listed with frequency not known. After an EU-wide Article 31 review (started October 2024, EC decision August 2025), suicidal ideation was confirmed as a side effect of finasteride 1 mg and 5 mg tablets at an unknown frequency, and a patient card is now included in 1 mg packs. Patients who experience mood changes should seek medical advice and, on finasteride 1 mg, stop treatment.
Reported during post-marketing use; frequency cannot be estimated from the available data.
The EU product information contraindicates use in women because finasteride can cause abnormalities of the external genitalia in a male foetus if taken during pregnancy.
About
Active ingredient: Finasteride · Dosages: 1 mg / day
Finasteride is a 5-alpha-reductase inhibitor: it reduces the conversion of testosterone into DHT, the hormone responsible for follicle miniaturisation in male androgenetic alopecia.
It's a continuous daily treatment — on discontinuation, effects fade over 6–12 months. A licensed doctor confirms the diagnosis, reviews the risks with you and rules out contraindications before prescribing.
How it helps
Targets DHT, the hormonal driver of pattern loss — not just the symptom.
Most men notice the shedding slows between months 3 and 6.
Effects are maintained with continuous use and periodic medical reviews.
What to expect
One 1 mg tablet daily. Results are assessed over months, not weeks — and your doctor follows up through your account chat.
Doses your doctor can prescribe
Safety first
Finasteride is an effective medicine — and like any medicine it carries risks. Your doctor screens for all of this before prescribing. Here's the honest picture, not just reassurance.
Adult men with mild-to-moderate androgenetic alopecia (male pattern hair loss).
Who should not take it
PRICING
€25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth. €35 one-off is available for sexual health.
ONGOING PLAN
€15/month
Billed €45 every 90 days · cancel anytime
For ongoing treatment and doctor-reviewed renewals.
Lowest monthly price we offer
Full refund if a review is not approved
WHAT'S INCLUDED
Full refund if a review is not approved
If a review is not approved, we refund that period's €45 fee and cancel the plan.
Note: The medication, if the doctor prescribes it, is paid separately at the pharmacy at the price it sets. Hi-Doctor does not sell medications.
HOW THE DOCTOR DECIDES
An EU-licensed doctor reads your questionnaire and answers in less than 2 hours on average.
If the doctor decides it is not safe to prescribe, the consultation fee is refunded in full.
Follow-up happens in the private chat inside your account, under GDPR. No WhatsApp, no SMS.
OTHER HAIR GROWTH TREATMENTS
Find out if it's right for you
Answer a few questions and a licensed EU doctor reviews your case in less than 2 hours on average. Refunded in full if it's not right for you.
HI-DOCTOR NEWSLETTER
At most 2 emails a month. No spam. Updates on online health, EU telemedicine, and clinical guides signed by licensed doctors.